Mass Spectrometry Imaging in Oncology Drug Discovery

Adv Cancer Res. 2017:134:133-171. doi: 10.1016/bs.acr.2016.11.005. Epub 2017 Jan 10.

Abstract

Over the last decade mass spectrometry imaging (MSI) has been integrated in to many areas of drug discovery and development. It can have significant impact in oncology drug discovery as it allows efficacy and safety of compounds to be assessed against the backdrop of the complex tumour microenvironment. We will discuss the roles of MSI in investigating compound and metabolite biodistribution and defining pharmacokinetic -pharmacodynamic relationships, analysis that is applicable to all drug discovery projects. We will then look more specifically at how MSI can be used to understand tumour metabolism and other applications specific to oncology research. This will all be described alongside the challenges of applying MSI to industry research with increased use of metrology for MSI.

Keywords: PK/PD; drug delivery; microenvironment.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacokinetics*
  • Drug Discovery*
  • Humans
  • Image Processing, Computer-Assisted / methods*
  • Mass Spectrometry / methods*
  • Molecular Imaging / methods*
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Neoplasms / pathology*
  • Tissue Distribution

Substances

  • Antineoplastic Agents